Tags

Type your tag names separated by a space and hit enter

Rectal NSAIDs for the prevention of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.
Surgeon. 2014 Jun; 12(3):141-7.S

Abstract

BACKGROUND AND PURPOSE

Acute pancreatitis is the most frequent complication of endoscopic retrograde cholangiopancreatography (ERCP). We conducted a meta-analysis to evaluate the efficacy and safety of rectal nonsteroidal anti-inflammatory drugs (NSAIDs) for the prevention of post-ERCP pancreatitis (PEP).

METHODS

PubMed and Embase databases were searched through April 2013. Results are reported as relative risk (RR) or weighted mean difference (WMD) with 95% confidence interval (95% CI). The primary outcome measure was the incidence of PEP. Secondary outcome measures included the severity of PEP and serum amylase level 2 h, 24 h after ERCP.

RESULTS

Seven trials containing 1846 patients were eligible. Rectal NSAIDs significantly reduced the incidence of PEP (RR 0.45, 95% CI 0.34-0.61, P < 0.001). The results were maintained in subsequent subgroup analysis. Rectal NSAIDs also was associated with a reduction in the incidence of mild PEP (RR 0.54, 95% CI 0.35-0.83, P = 0.005), moderate to severe PEP (RR 0.39, 95% CI 0.22-0.70, P = 0.002), or serum amylase level 2 h after ERCP (WMD -91.09 IU/L, 95% CI -149.78 to -32.40, P = 0.002).

CONCLUSIONS

Rectal NSAIDs reduced the incidence and severity of PEP, as well as serum amylase level 2 h after ERCP.

Authors+Show Affiliations

Department of Biliary Vascular Surgery, Shenjing Hospital of China Medical University, Shenyang 110004, China.Department of Biliary Vascular Surgery, Shenjing Hospital of China Medical University, Shenyang 110004, China.Department of General Surgery, Central Hospital of Shenyang Medical College, Shenyang 110004, China.Department of Biliary Vascular Surgery, Shenjing Hospital of China Medical University, Shenyang 110004, China.Department of Biliary Vascular Surgery, Shenjing Hospital of China Medical University, Shenyang 110004, China. Electronic address: makai0311@126.com.

Pub Type(s)

Journal Article
Meta-Analysis
Review

Language

eng

PubMed ID

24332479

Citation

Sun, Hong-Li, et al. "Rectal NSAIDs for the Prevention of post-ERCP Pancreatitis: a Meta-analysis of Randomized Controlled Trials." The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland, vol. 12, no. 3, 2014, pp. 141-7.
Sun HL, Han B, Zhai HP, et al. Rectal NSAIDs for the prevention of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. Surgeon. 2014;12(3):141-7.
Sun, H. L., Han, B., Zhai, H. P., Cheng, X. H., & Ma, K. (2014). Rectal NSAIDs for the prevention of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland, 12(3), 141-7. https://doi.org/10.1016/j.surge.2013.10.010
Sun HL, et al. Rectal NSAIDs for the Prevention of post-ERCP Pancreatitis: a Meta-analysis of Randomized Controlled Trials. Surgeon. 2014;12(3):141-7. PubMed PMID: 24332479.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rectal NSAIDs for the prevention of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. AU - Sun,Hong-Li, AU - Han,Bing, AU - Zhai,Hong-Peng, AU - Cheng,Xin-Hua, AU - Ma,Kai, Y1 - 2013/12/09/ PY - 2013/08/24/received PY - 2013/10/26/revised PY - 2013/10/28/accepted PY - 2013/12/17/entrez PY - 2013/12/18/pubmed PY - 2015/8/26/medline KW - Endoscopic retrograde cholangiopancreatography KW - Meta-analysis KW - Nonsteroidal anti-inflammatory drugs KW - Pancreatitis KW - Rectal SP - 141 EP - 7 JF - The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland JO - Surgeon VL - 12 IS - 3 N2 - BACKGROUND AND PURPOSE: Acute pancreatitis is the most frequent complication of endoscopic retrograde cholangiopancreatography (ERCP). We conducted a meta-analysis to evaluate the efficacy and safety of rectal nonsteroidal anti-inflammatory drugs (NSAIDs) for the prevention of post-ERCP pancreatitis (PEP). METHODS: PubMed and Embase databases were searched through April 2013. Results are reported as relative risk (RR) or weighted mean difference (WMD) with 95% confidence interval (95% CI). The primary outcome measure was the incidence of PEP. Secondary outcome measures included the severity of PEP and serum amylase level 2 h, 24 h after ERCP. RESULTS: Seven trials containing 1846 patients were eligible. Rectal NSAIDs significantly reduced the incidence of PEP (RR 0.45, 95% CI 0.34-0.61, P < 0.001). The results were maintained in subsequent subgroup analysis. Rectal NSAIDs also was associated with a reduction in the incidence of mild PEP (RR 0.54, 95% CI 0.35-0.83, P = 0.005), moderate to severe PEP (RR 0.39, 95% CI 0.22-0.70, P = 0.002), or serum amylase level 2 h after ERCP (WMD -91.09 IU/L, 95% CI -149.78 to -32.40, P = 0.002). CONCLUSIONS: Rectal NSAIDs reduced the incidence and severity of PEP, as well as serum amylase level 2 h after ERCP. SN - 1479-666X UR - https://www.unboundmedicine.com/medline/citation/24332479/Rectal_NSAIDs_for_the_prevention_of_post_ERCP_pancreatitis:_a_meta_analysis_of_randomized_controlled_trials_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1479-666X(13)00155-8 DB - PRIME DP - Unbound Medicine ER -